يعرض 1 - 20 نتائج من 48 نتيجة بحث عن '"Sauder, K A"', وقت الاستعلام: 0.57s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
    Academic Journal
  3. 3
  4. 4
    Academic Journal
  5. 5
    Academic Journal
  6. 6
    Conference
  7. 7
    Conference
  8. 8
    Academic Journal
  9. 9
    Academic Journal
  10. 10
    Academic Journal
  11. 11
    Academic Journal

    مصطلحات موضوعية: Otolaryngology, Pharmacy and Pharmacology, Health Sciences

    وصف الملف: application/pdf

    Relation: Waljee, A. K.; Liu, B.; Sauder, K.; Zhu, J.; Govani, S. M.; Stidham, R. W.; Higgins, P. D. R. (2018). "Predicting corticosteroid‐free endoscopic remission with vedolizumab in ulcerative colitis." Alimentary Pharmacology & Therapeutics 47(6): 763-772.; http://hdl.handle.net/2027.42/142532; Alimentary Pharmacology & Therapeutics; Loftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004; 126: 1504 ‐ 1517.; Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013; 369: 699 ‐ 710.; Stallmach A, Langbein C, Atreya R, et al. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease – a prospective multicenter observational study. Aliment Pharmacol Ther. 2016; 44: 1199 ‐ 1212.; Amiot A, Serrero M, Peyrin‐Biroulet L, et al. One‐year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther. 2017; 46: 310 ‐ 321.; Dulai PS, Singh S, Jiang X, et al. The real‐world effectiveness and safety of vedolizumab for moderate‐severe Crohn’s disease: results from the US VICTORY consortium. The American journal of gastroenterology. 2016; 111: 1147 ‐ 1155.; ENTYVIO (VEDOLIZUMAB) FOR INJ 300MG SDV. metromedicalorder.com. https://www.metromedicalorder.com/entyvio-vedolizumab-for-inj-300mg-sdv.html. Accessed March 20, 2017.; Cohen BL, Sachar DB. Update on anti‐tumor necrosis factor agents and other new drugs for inflammatory bowel disease. BMJ. 2017; 357: j2505. https://doi.org/10.1136/bmj.j2505; CSDR: Clinical Study Data Request. https://clinicalstudydatarequest.com/.; Breiman L. Random forests. Mach Learn. 2001; 45: 5 ‐ 32.; Liaw A, Wiener M. Classification and regression by random forest. R News. 2002; 2: 18 ‐ 22.; Romero J, Lopez P, Vazquez Noguera JL, Cappo C, Pinto‐Roa PD, Villalba C. Integrated, reliable and cloud‐based personal health record: a scoping review. HIIJ. 2016; 5: 01 ‐ 20.; Stidham RW, Lee TCH, Higgins PDR, et al. Systematic review with network meta‐analysis: the efficacy of anti‐tumour necrosis factor‐alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2014; 39: 660 ‐ 671.; Stidham RW, Lee TCH, Higgins PDR, et al. Systematic review with network meta‐analysis: the efficacy of anti‐TNF agents for the treatment of Crohn’s disease. Aliment Pharmacol Ther. 2014; 39: 1349 ‐ 1362.; Olivera P, Danese S, Peyrin‐Biroulet L. JAK inhibition in inflammatory bowel disease. Exp Rev Clin Immunol. 2017; 13: 693 ‐ 703.; Furfaro F, Gilardi D, Allocca M, et al. IL‐23 Blockade for Crohn s disease: next generation of anti‐cytokine therapy. Exp Rev Clin Immunol. 2017; 13: 457 ‐ 467.

  12. 12
  13. 13
    Academic Journal
  14. 14
    Academic Journal
  15. 15
    Academic Journal
  16. 16
    Academic Journal
  17. 17
    Academic Journal
  18. 18
    Academic Journal
  19. 19
    Academic Journal
  20. 20